FMP
NASDAQ
Inactive Equity
SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. The company designs, develops, and manufactures genetic analysis technologies. It offers true single molecule sequencing (tSMS) platform, which offers a single molecule solution for DNA and RNA sequencing. The company has a collaboration agreement with Bernstein Laboratory, Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc., and Tetracore, Inc. It serves academic and government institutions, hospitals and medical centers, pharmaceutical and biotechnology companies, and non-profit research organizations. The company was founded in 2013 and is based in Billerica, Massachusetts.
6.6 USD
-1.6709 (-25.32%)
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)